QIBA CT Volumetry Biomarker Ctte (BC) Call
17 August 2015 at 11 AM CT
Draft Call Summary

In attendance:  
**Samuel G. Armato, III, PhD (Co-Chair)**  
Matthew Fuld, PhD  
James Mulshine, MD  
Joe Koudelik

**Greg Goldmacher, MD, PhD, MBA (Co-Chair)**  
Rudresh Jarecha, MBBS  
Nancy Obuchowski, PhD  
Julie Lisiecki

**Jenifer Siegelman, MD, MPH (Co-Chair)**  
Philip F. Judy, PhD  
Eric Perlman, MD  
Greg Goldmacher, MD, PhD, MBA (Co-Chair)

**Maria Athelogou, PhD**  
John Lu, PhD  
Adele Peskin, PhD

**Hubert Beaumont, PhD**  
Michael McNitt-Gray, PhD  
Nicholas Petrick, PhD

**Charles Fenimore, PhD**  
P. David Mozley, MD  
Hiromitsu Tan’nai, MD  

RSNA:

**Samuel G. Armato, III, PhD (Co-Chair)**  
Matthew Fuld, PhD  
James Mulshine, MD  
Joe Koudelik

**Greg Goldmacher, MD, PhD, MBA (Co-Chair)**  
Rudresh Jarecha, MBBS  
Nancy Obuchowski, PhD  
Julie Lisiecki

**Jenifer Siegelman, MD, MPH (Co-Chair)**  
Philip F. Judy, PhD  
Eric Perlman, MD  
Greg Goldmacher, MD, PhD, MBA (Co-Chair)

**Maria Athelogou, PhD**  
John Lu, PhD  
Adele Peskin, PhD

**Hubert Beaumont, PhD**  
Michael McNitt-Gray, PhD  
Nicholas Petrick, PhD

**Charles Fenimore, PhD**  
P. David Mozley, MD  
Hiromitsu Tan’nai, MD

Ad hoc Physics Discussion
- An *ad hoc* call was held recently for CT Volumetry BC physicists and engineers
- Results from this collaborative work on iterative reconstruction will be incorporated into the Profile

Profile Question Re: Conformance Recommendation
- Level at which to set the “QIBA bar” still to be determined
  - “Easier” initial conformance, with requirements increasing in complexity over time? *or*
  - “More difficult” conformance standard so that it is more meaningful?
  - BC leadership to review feedback from BC members

Suggested Topics for CT Volumetry BC Future Discussion:
- Liver phantom project update (late September or early Oct)
- Virtual lesion project update
- Profile – Discussion of where to set the pass threshold for algorithms
- Continuing the algorithms challenges using virtual lesion data
- The use of data from clinical trials – Pharma and/or ACRIN (outcome metrics needed)
- Planning the feasibility portion of field test
- Lessons learned for developing Profiles (invite process leaders and other Profile authors)

QIBA Group 3A: Future Direction
- Collaborative challenges with the synthetic lesions group (Dr. Samei) were proposed to continue the algorithm challenge effort
- Connections with pharma to access clinical data were suggested as a new pathway for challenges
  - Unknown intrinsic factors for each patient can also add challenges
  - Organizing a collaboration with pharma may prove difficult due to limited resources and the large scale of trial data needed

Proposed Poster Topics for QIBA kiosk at RSNA 2015
- Group 3A challenges, update on most recent clinical challenge (Dr. Athelogou)
- Liver phantom project update (Drs. Zhao and Petrick)
- Synthetic lesions project update (Dr. Samei)
- Small Lung Nodule Profile update (Dr. Mulshine)

Action items
- CT Volumetry leadership recommendation re: conformance requirements (Drs. Goldmacher, Siegelman)
- Revised vendor physics assessment procedure - (Drs. Boedeker and Samei, Mr. O’Donnell)
- Invite project PIs for upcoming presentations to the BC - (Dr. Goldmacher)
- Suggestions for fall call schedule topics to: jlisiecki@rsna.org

Next Calls:
- **August 31st**: Continuation of discussion on CT Volumetry conformance recommendation
- Other topics: Progress / future planning for the Profile, RSNA 2015 QIBA poster, BC topics for the fall